JPMorgan analyst Eric Joseph reaffirmed an Underweight rating for Novavax Inc. (NASDAQ:NVAX) with a price target of $7. This ...

The Food and Drug Administration has granted full approval to Novavax, Inc. (NASDAQ:NVAX) COVID-19 vaccine, but with notable ...

Novavax (NVAX) stock in focus as the U.S. FDA approves its COVID-19 vaccine Nuvaxovid for high-risk groups in the U.S. Read ...

Novavax (NASDAQ:NVAX) shares jumped more than 17% on Monday after the U.S. Food and Drug Administration granted full approval ...

Novavax (NVAX) shares climbed more than 17% premarket on Monday after the long-delayed approval of its COVID-19 vaccine from ...

In the options pits, NVAX has already seen quadruple the overall options volume it typically sees in an entire session, with ...

After a prolonged wait, American company Novavax (Nasdaq: NVAX) has received full approval from the US regulator for its ...

Shares of vaccine makers saw an uptick in the latest trading session, with Moderna Inc (BMV:MRNA). (NASDAQ:MRNA) leading the ...

Novavax (NASDAQ:NVAX), a leading player in the biopharmaceutical industry, has seen increasing institutional interest in ...

Investors reacted positively to the news, as the FDA’s approval not only enhances Novavax’s product offering but also solidifies its partnership with Sanofi, a key player in the vaccine market. The ...

Live Updates Live Coverage Has Ended Markets Turn Positive 1:37 pm by The stock market has managed to crawl its way back ...

The Food and Drug Administration has granted full approval to Novavax, Inc. (NASDAQ:NVAX) COVID-19 vaccine, but with notable limitations. Previously available under emergency use authorization for ...